Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI)

What Was Tested

Researchers studied Exenatide in this randomized controlled trial publication.

Remote ischemic conditioning (RIC) and the GLP-1 analog exenatide activate different cardioprotective pathways and may have additive effects on infarct size (IS).

The researchers designed a two-by-two factorial, randomized controlled, blinded, multicenter, clinical trial.

Who Took Part

According to the abstract, 378 patients were involved.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

Patients with ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention (PPCI) within 6 h of symptoms were randomized to RIC or sham procedure and exenatide or matching placebo.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.

Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Exenatide study, the assignments were hidden from both participants and investigators until the end.

Some patients received a placebo instead of Exenatide, giving a reference point.

Running at several centres spread the Exenatide study over different clinics and patient groups.

What Was Measured

The primary outcome was IS measured by late gadolinium enhancement in cardiac magnetic resonance performed 3-7 days after PPCI.

The secondary outcomes were myocardial salvage index, transmurality index, left ventricular ejection fraction and relative microvascular obstruction volume.

The subject headings attached to it are Arm, Combined Modality Therapy, Exenatide, Incretins, Ischemic Preconditioning, Magnetic Resonance Imaging, Cine and Myocardium.

Author keywords: Primary percutaneous coronary intervention, Remote ischemic conditioning and ST-segment elevation acute myocardial infarction.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exenatide in 378 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2021 (Basic research in cardiology), a journal based in Germany.

More context: the Exenatide compound page, all human trials.